Nicholls et al. reported that CCL3 binding sites were reduced on CML CD34+ cells, compared with normal CD34+ population and proposed that reduced CCL3 binding sites were responsible for reduced responsiveness of CML progenitor cells to CCL3 [86]. The gene discussed is CCL3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.